approval · primary record
VANCOMYCIN HYDROCHLORIDE
3 approval events · latest 2026-08-18
| Agency | FDA |
|---|---|
| Submission type | NDA |
| Latest action | 2026-08-18 |
| Approval events | 3 |
| Brand | TYZAVAN |
| Sponsor | HIKMA |
| Route | INTRAVENOUS |
Approval history
3 actions on record. The drug is the stable record; each action below is an event with its own date, so this URL keeps working as new actions arrive.
| Date | Agency | Type | Brand | Sponsor | Route |
|---|---|---|---|---|---|
| 2026-08-18 | FDA | NDA | TYZAVAN | HIKMA | INTRAVENOUS |
| 2026-06-09 | FDA | NDA | VANCOMYCIN HYDROCHLORIDE IN PLASTIC CONTAINER | BAXTER HLTHCARE | INTRAVENOUS |
| 2025-05-29 | FDA | NDA | VANCOMYCIN HYDROCHLORIDE | ZHEJIANG NOVUS PHARM | INTRAVENOUS, ORAL |
Provenance
- Source: openFDA Drugs@FDA
- Fetched at: 2026-10-30T00:29:34.037Z
- Licence class: public-domain
- Verdict: primary-source
- Entity id: approval:vancomycin-hydrochloride
This record is rendered from the AEaH spine. If the source is unreachable the page is not generated.
Same entity, elsewhere in the suite
- Vancomycin Hydrochloride · compound